TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial and operating results for the third quarter of 2008. The Company reported a net loss of $21.1 million, or $0.27 per share (basic and diluted), for the third quarter of 2008 compared with a net loss of $35.8 million, or $0.54 per share (basic and diluted), for the third quarter of 2007. The Company reported a net loss of $51.2 million, or $0.65 per share (basic and diluted), for the nine months ended September 30, 2008 compared with a net loss of $92.5 million, or $1.40 per share (basic and diluted), for the same period in 2007.
